On March 9, Flex Pharma, Inc. (NASDAQ:FLKS) announced that Chairman and Chief Executive Officer Christoph Westphal M.D. Ph.D. has established a pre-arranged personal stock purchasing plan to acquire shares of the Company’s stock. The purchasing plan is intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934 as amended which enables securities holders to adopt pre-arranged stock purchasing plans for the acquisition of shares on a non-discretionary basis. On Monday shares of Flex Pharma, Inc. (NASDAQ:FLKS) closed at $21.63.
On March 5, ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced that it has acquired the approved abbreviated new drug application (“ANDA”) for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, previously marketed by Teva Pharmaceuticals. According to IMS Health, the overall market for this product was approximately $39 million in 2014. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in last trading activity advanced 4.34% to close at $62.95. Company weekly performance is -2.01% while its quarterly performance stands at 21.17%. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is -12.30% away from its 52 week high.
On March 5, AOL Inc. (NYSE:AOL) Canada declared that the release of the newest international initiative from MAKERS, the global storytelling platform and leading collection of women’s stories assembled online. MAKERS Canada (makers.com/Canada) will emphasize and celebrate trailblazing Canadian women and provide a diverse and unique voice in market as the first female-focused platform of its kind in the country. On Monday shares of AOL Inc. (NYSE:AOL) closed at $38.85. Company’s sales growth for last 5 years was -4.90% and EPS growth for next 5 years is recorded as 9.53%.
On March 12, Constellium N.V. (NYSE:CSTM) reported fourth-quarter net loss attributable to owners of the company of 17 million euros or 0.17 euro per share, compared to net income of 32 million euros or 0.30 euro per share a year ago. Constellium N.V (NYSE:CSTM) institutional ownership stands at 89.70%. In last trading activity company’s stock closed at $20.07.
MLV & Co restated their buy rating on shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) in a report issued on Monday. They currently have a $54.00 target price on the stock. On last trading day Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) advanced 12.39% to close at $31.56. Its volatility for the week is 8.45% while volatility for the month is 5.52%. Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) monthly performance is 15.82%.